HRYZ Biotech Co. Report issue

For profit Phase 1
Founded: ShenZhen China (2013)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2017
NCT03034304
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

dendritic cells loaded with 17 antigens (1 trial)

ifosfamide (ifex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoma (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2